UNLABELLED: The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in clinical practice with 90Y-ibritumomab tiuxetan for non-Hodgkin's lymphoma, using appropriate dosimetric approaches available. METHODS: The single-view effective point source method, including background subtraction, is used for planar quantification of renal activity. Since the high uptake in the liver affects the activity estimate in the right kidney, the dose to the left kidney serves as a surrogate for the dose to both kidneys. Calculation of absorbed dose is based on the Medical Internal Radiation Dose methodology with adjustment for patient kidney mass. RESULTS: The median dose to kidneys, based on the left kidney only, is 2.1 mGy/MBq (range, 0.92-4.4), whereas a value of 2.5 mGy/MBq (range, 1.5-4.7) is obtained, considering the activity in both kidneys. CONCLUSIONS: Irrespective of the method, doses to kidneys obtained in the present study were about 10 times higher than the median dose of 0.22 mGy/MBq (range, 0.00-0.95) were originally reported from the study leading to Food and Drug Administration approval. Our results are in good agreement with kidney-dose estimates recently reported from high-dose myeloablative therapy with 90Y-ibritumomab tiuxetan.
UNLABELLED: The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in clinical practice with 90Y-ibritumomab tiuxetan for non-Hodgkin's lymphoma, using appropriate dosimetric approaches available. METHODS: The single-view effective point source method, including background subtraction, is used for planar quantification of renal activity. Since the high uptake in the liver affects the activity estimate in the right kidney, the dose to the left kidney serves as a surrogate for the dose to both kidneys. Calculation of absorbed dose is based on the Medical Internal Radiation Dose methodology with adjustment for patient kidney mass. RESULTS: The median dose to kidneys, based on the left kidney only, is 2.1 mGy/MBq (range, 0.92-4.4), whereas a value of 2.5 mGy/MBq (range, 1.5-4.7) is obtained, considering the activity in both kidneys. CONCLUSIONS: Irrespective of the method, doses to kidneys obtained in the present study were about 10 times higher than the median dose of 0.22 mGy/MBq (range, 0.00-0.95) were originally reported from the study leading to Food and Drug Administration approval. Our results are in good agreement with kidney-dose estimates recently reported from high-dose myeloablative therapy with 90Y-ibritumomab tiuxetan.
Authors: J A Siegel; S R Thomas; J B Stubbs; M G Stabin; M T Hays; K F Koral; J S Robertson; R W Howell; B W Wessels; D R Fisher; D A Weber; A B Brill Journal: J Nucl Med Date: 1999-02 Impact factor: 10.057
Authors: Gregory A Wiseman; Ellen Kornmehl; Bryan Leigh; William D Erwin; Donald A Podoloff; Stewart Spies; Richard B Sparks; Michael G Stabin; Thomas Witzig; Christine A White Journal: J Nucl Med Date: 2003-03 Impact factor: 10.057
Authors: A Kojima; Y Takaki; M Matsumoto; S Tomiguchi; M Hara; O Shimomura; Y Koga; M Takahashi Journal: Med Phys Date: 1993 Jan-Feb Impact factor: 4.071
Authors: Sui Shen; Andres Forero; Albert F LoBuglio; Hazel Breitz; M B Khazaeli; Darrell R Fisher; Wenquan Wang; Ruby F Meredith Journal: J Nucl Med Date: 2005-04 Impact factor: 10.057
Authors: Marta Cremonesi; Mahila Ferrari; Chiara Maria Grana; Anna Vanazzi; Mike Stabin; Mirco Bartolomei; Stefano Papi; Gennaro Prisco; Pier Francesco Ferrucci; Giovanni Martinelli; Giovanni Paganelli Journal: J Nucl Med Date: 2007-11 Impact factor: 10.057
Authors: P C van Reenen; M G Lötter; A D Heyns; F de Kock; C Herbst; H Kotzé; H Pieters; P C Minnaar; P N Badenhorst Journal: Eur J Nucl Med Date: 1982
Authors: Giovanni Paganelli; Concetta De Cicco; Mahila E Ferrari; Giuseppe Carbone; Gianmatteo Pagani; Maria Cristina Leonardi; Marta Cremonesi; Annamaria Ferrari; Monica Pacifici; Amalia Di Dia; Rita De Santis; Viviana Galimberti; Alberto Luini; Roberto Orecchia; Stefano Zurrida; Umberto Veronesi Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-04 Impact factor: 9.236
Authors: C Chiesa; F Botta; A Coliva; M Maccauro; L Devizzi; A Guidetti; C Carlo-Stella; E Seregni; M A Gianni; E Bombardieri Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-20 Impact factor: 9.236
Authors: Donika Plyku; David M Loeb; Andrew R Prideaux; Sébastien Baechler; Richard L Wahl; George Sgouros; Robert F Hobbs Journal: Cancer Biother Radiopharm Date: 2015-11 Impact factor: 3.099
Authors: Sebastien Baechler; Robert F Hobbs; Ariane Boubaker; Franz Buchegger; Bin He; Eric C Frey; George Sgouros Journal: Med Phys Date: 2012-10 Impact factor: 4.506